Thousands of men across England will soon benefit from new NHS prostate cancer radiotherapy, a major advancement that could significantly reduce treatment time while maintaining effective cancer control.
The National Health Service England has announced a nationwide rollout of Stereotactic Ablative Radiotherapy (SABR), a highly targeted form of radiation treatment that can reduce the number of required radiotherapy sessions from more than 20 to just five. The move marks an important milestone in NHS England cancer care, offering eligible prostate cancer patients faster treatment and fewer hospital visits.
The introduction of new NHS prostate cancer radiotherapy follows successful clinical studies and is expected to improve patient experiences while helping the NHS manage growing demand for cancer services.
NHS SABR Rollout Brings Advanced Cancer Prostate Treatment
Under the new NHS SABR rollout, all 48 radiotherapy centres across England are expected to begin offering SABR to eligible patients within the coming months.
SABR, stereotactic radiotherapy, delivers high doses of radiation directly to cancerous tissue with exceptional precision. By targeting tumors from multiple angles, SABR treatment minimizes exposure to nearby healthy organs and tissues.
According to NHS England, approximately 17,500 men diagnosed annually with low- or intermediate-risk prostate cancer could be eligible for the treatment. Health officials estimate that around 3,500 patients may choose this option each year.
The new prostate cancer SABR rollout by the NHS is aimed specifically at men whose cancer remains localized and has not spread beyond the prostate.
How NHS Precision Radiotherapy for Prostate Cancer Is Different
Traditional prostate cancer radiotherapy often requires patients to attend treatment sessions over several weeks. In contrast, NHS precision radiotherapy for prostate cancer can usually be completed in five treatments delivered over about two weeks.
Key advantages of SABR treatment include:
- Fewer hospital visits
- Reduced disruption to daily life
- More targeted radiation delivery
- Lower risk of damage to surrounding healthy tissue
- Increased treatment capacity within NHS facilities
“This technology lets us focus a powerful and precise beam of radiotherapy directly on to the cancer, limiting the damage to healthy cells,” said Professor Peter Johnson, NHS National Clinical Director for Cancer, highlighting the significance of the technology.
He added that reducing treatment by 15 sessions could help many patients return to their normal lives more quickly.
The benefits of new NHS prostate cancer radiotherapy are already being seen among participants enrolled in ongoing clinical studies.
One patient, 70-year-old Edwin Lambert from Suffolk, received SABR as part of a trial after being diagnosed with prostate cancer in 2025. Following hormone therapy, he underwent the targeted radiotherapy treatment and reported that it was easier to manage than conventional treatment approaches.
Prostate Cancer Research Continues With SABR Treatment
The new NHS prostate cancer radiotherapy rollout focuses on low- and intermediate-risk prostate cancer, but researchers are exploring whether SABR can benefit additional patient groups.
Ongoing prostate cancer research is investigating the use of stereotactic radiotherapy for men with higher-risk disease and cancers that have begun spreading beyond the prostate. Positive results could further expand treatment options in the coming years.
Recently, there have been broader developments in prostate cancer care. Johnson & Johnson is researching a prostate cancer drug for High-Risk Patients, promising advances in treatment innovation.
New Hope For Prostate Cancer Treatment
The NHS radiotherapy rollout for prostate cancer is expected to deliver benefits beyond individual patient outcomes.
NHS England estimates that the adoption of new NHS prostate cancer radiotherapy could free up approximately 50,000 radiotherapy appointments each year. This additional capacity may help reduce waiting times and allow cancer centres to treat more patients efficiently.
By reducing treatment sessions, improving convenience, and maintaining precision targeting, the NHS SABR Rollout could benefit both patients and the healthcare system.
The nationwide introduction of new NHS prostate cancer radiotherapy could be the most significant advancement in prostate cancer care in recent times.
